Naphthalene‐4 H ‐Chromene Molecular Hybrids as Dual Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease
Drug Development Research · 2026
DOI: 10.1002/ddr.70338 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, 2026. Verfasst von Vinod Ugale und 7 weiteren Autor:innen. Beteiligte Einrichtung: R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, India. Hauptthemen laut MEDLINE: Cholinesterase Inhibitors, Alzheimer Disease, Naphthalenes, Benzopyrans. Die Arbeit nennt 26 Literaturangaben. Gefördert von: Rajiv Gandhi Science and Technology Commission, Department of Science and Technology (DST)-Science and Engineering Research Board (SERB), Kavayitri Bahinabai Chaudhari North Maharashtra University (KBCNMU).
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline associated with cholinergic dysfunction. Herein, we have designed and synthesized series of 4‐(naphthalen‐1‐yl)−4 H ‐chromene derivatives 4 ( a‐n ) by a one‐pot three‐component reaction with adequate synthetic yield and purity. Naphthalene‐chromene hybrids were synthesized by formation of two C─C bonds and one C─O bond in a single synthetic step. All synthesized compounds were tested for safety and efficacy using in vitro and in vivo studies. Compounds were found devoid of cytotoxicity in BV‐2 cells. Most of the synthesized compounds have shown moderate to good inhibitory activity against cholinesterase enzymes. These compounds were found to be more selective towards acetylcholinesterase (AChE) compared to butyrylcholinesterase (BuChE). Compound 4 m has shown highest inhibitory potency against AChE (AChE, IC 50 = 1.08 µM; BuChE, IC 50 = 82.59 µM). The prototype compound ( 4 m ) from in‐vitro screening was found to be safe in acute oral toxicity followed by histopathological analysis. Compound 4 m was evaluated for in vivo efficacy in scopolamine‐induced cognitive impairment model in mice. It significantly reversed the cognitive deficit in neurobehavioral tests. Pre‐treatment with 4 m have balanced key biochemical markers involved in the oxidative stress and cognitive functions. The compound 4 m alleviated neuronal tissue damage caused by scopolamine as indicated in the histological study. Molecular docking analysis also reconfirmed the binding affinity of 4 m at cholinesterase enzymes. Taken together, these findings supported the emergence of 4 m as a potential cholinesterase inhibitor for the treatment of AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, India.
- Bioprospecting Group, Agharkar Research Institute, Savitribai Phule Pune University, Pune, India.
- Department of Chemistry, School of Science, Gitam Deemed to be University, Hyderabad, India.
- Rajarshi Shahu College of Pharmacy, Buldana, India.
ORCID-Profile: Vinod Ugale, Kalpesh Patil, Pedavenkatagari Narayana Reddy
Förderung
- Rajiv Gandhi Science and Technology Commission
- Department of Science and Technology (DST)-Science and Engineering Research Board (SERB)
- Kavayitri Bahinabai Chaudhari North Maharashtra University (KBCNMU)
Zitieren
APA
Ugale, V., Sharon, N., Salunkhe, C., Salunkhe, J., Lokwani, D., Patil, K., Reddy, P. N., & Kulkarni, P. (2026). Naphthalene‐4 H ‐Chromene Molecular Hybrids as Dual Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease. Drug Development Research. https://doi.org/10.1002/ddr.70338
Vancouver
Ugale V, Sharon N, Salunkhe C, Salunkhe J, Lokwani D, Patil K, et al. Naphthalene‐4 H ‐Chromene Molecular Hybrids as Dual Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease. Drug Development Research. 2026. doi:10.1002/ddr.70338
BibTeX
@article{Ugale2026,
author = {Ugale, Vinod and Sharon, Nissi and Salunkhe, Chandradip and Salunkhe, Jotiram and Lokwani, Deepak and Patil, Kalpesh and Reddy, Pedavenkatagari Narayana and Kulkarni, Prasad},
title = {Naphthalene‐4 H ‐Chromene Molecular Hybrids as Dual Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease},
journal = {Drug Development Research},
year = {2026},
doi = {10.1002/ddr.70338}
}
EUVIMED